September 23, 2025
Biopharmaceutical company Axsome Therapeutics Inc. and its shareholders have asked a New York federal court to approve a $7.75 million settlement to resolve investors' claims that Axsome hid issues related to gaining regulatory approval for its migraine drug.
September 26, 2023
A New York federal judge on Monday tossed a proposed securities class action alleging that biopharmaceutical company Axsome hid issues about its migraine drug, leading to a significant stock price drop, saying the lead plaintiff suffered no loss since he sold his shares at an inflated price.